![]() Others argue the rules made the work of independent television production companies much more difficult because smaller companies could never afford the deficit financing required unless they received network assistance. Some argue the rules brought about a golden era of independent television production by companies such as MTM Enterprises ( The Mary Tyler Moore Show) and Norman Lear's Tandem Productions ( All in the Family). The rules changed the power relationships between networks and television producers, who often had to agree to exorbitant profit participation in order to have their shows aired. The rules also led to the networks spun-off their syndicated divisions, like CBS' CBS Enterprises was later renamed as Viacom in 1971 and later spun-off, ABC's ABC Films was sold to its five executives and later renamed as Worldvision Enterprises and NBC's syndicated division NBC Films was later sold to National Telefilm Associates for $7.5 million, both occurred in March 1973. The rules also prohibited networks from airing syndicated programming they had a financial stake in. The FCC sought to prevent the Big Three television networks from monopolizing the broadcast landscape by preventing them from owning any of the programming that they aired in prime time. The Financial Interest and Syndication Rules, widely known as the fin-syn rules, were a set of rules imposed by the Federal Communications Commission in the United States in 1970. is headquartered in Rockville, Maryland.Set of rules imposed by the Federal Communications Commission in 1970 Louis to conduct a Phase 1b/2a clinical trial of SYN-004. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center and a clinical trial agreement with Washington University School of Medicine in St. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics SYN-005 for the prevention and treatment of pertussis and VCN-11 to treat cancer. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. ![]() The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. 10 Recession-Proof Stocks That Will Let You Wait Out the Bear.7 Stocks with the Pricing Power to Push Through High Inflation.7 Blue-Chip Dividend Stocks That Won’t be Impacted by Rising Interest Rates.7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time.7 Stocks to Buy to Outrun Rising Interest Rates.7 Sports Betting Stocks to Buy for Their Long-Term Possibilities.7 Water Stocks to Buy as the World Dries Up.7 Solar Stocks Leading the Clean Energy Boom.7 Railroad Stocks to Keep Your Portfolio Chugging Along. ![]() ![]() 7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed.7 Streaming Stocks That Will Stand up to Streaming Fatigue.3 Stocks Growing Their Businesses for 2023.Small-Cap Catalyst Pharma Is Among Market's Best Price Performers.Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower.3 Safe Earnings Plays for a Risk-Off Market.Vertex Shares Higher On Optimism About CRISPR Partnership.Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear.Too Soon: 3 Reasons to Wait on DocuSign Stock.Hot Potato: Lamb Weston Stock Confirms a Top. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |